NANOX

Dawn of early detection healthcare

Corporate Presentation

January 2021

Disclaimers

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or NANO-X IMAGING LTD ("Nanox" or the 'Company") or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all inclusive or to contain all of the information about the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Information Statement

Statements contained in this presentation concerning expectations, beliefs, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact are "forward-looking statements." These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "target," "project," "forecast," "seek," "will," "may," "should," "could," "would" or similar expressions. Although Nanox believes that the expectations and assumptions reflected in these statements are reasonable, these expectations or forecasts of future performance may not prove to be correct. Forward-looking statements are subject to many risks and uncertainties, and actual results may differ materially from the results discussed in forward-looking statements. The following are among the important factors that could cause actual results to differ materially from the forward-looking statements: risks related to Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-Ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; the market acceptance of the Nanox.ARC and the proposed pay-per-scan business model; Nanox's expectations regarding collaborations with third-parties and their potential benefits; Nanox's ability to conduct business globally; the impact of general economic conditions, general conditions in the medical technology and imaging industries; the impact of the COVID-19 pandemic on the Company's business operations; changes in the global and regional regulatory environments in the jurisdictions in which Nanox does or plans to do business; and market volatility, fluctuations in costs and changes to the competitive environment, among others. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Other risks and uncertainties of which Nanox is not currently aware may also affect these forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and Nanox is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

These risks and uncertainties are described more fully under the caption "Risk Factors" in the Company's filings with the Securities and Exchange Commission. Other risks and uncertainties of which the Company is not currently aware may also affect Company's forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Market and Industry Data and Customer Information

This presentation has been prepared by Nanox and includes market data and other information from sources believed by the company to be reliable. For example, industry and market data, including Nanox's own research, and surveys or industry publications and surveys as well as public information about Nanox's customers and discussion with them. Some data are also based on Nanox's good-faith estimates, which are derived from Nanox's review of internal sources as well as the other sources described above. Although Nanox believes these sources are reliable, Nanox has not independently verified the information is accurate and complete. As a result, you should be aware that market share, ranking and other similar data set forth in this presentation, and estimates and beliefs based on such data may not be reliable.

Nanox at a glance

The What

Nanox aims to build a global infrastructure for medical imaging

Utilizing innovative, patent protected and disruptive technology, Nanox can offer medical technology that expands access, resulting in better outcomes and lower costs.

Until today, technology was the barrier to medical imaging availability.

Nanox believes it has broken that barrier.

With global execution expected to start this year Nanox invites partners to join the potentially next revolution in preventive healthcare.

Unmet need

Large deficit of medical imaging systems due to high system costs

2/3 of the world's population has no meaningful access to medical imaging.

Weeks and months of wait times for radiology diagnostics results.

Game changing tech

A novel digital X-Ray source replacing an analog X-Ray that has been used for over 100 years enables significant cost reduction

A new breed of medical imaging infrastructure that can be deployed in mass due to significantly lower costs and small footprint coupled with a radiology services cloud platform

Upcoming Milestones

We are targeting several near term value catalysts such as FDA approval and commercialization

Q1 2021

- Deals signed
- FDA approved
- First units shipped (H2 2021)
- Manufacturing ramp-up
- Global deployments

2021-2024

- 15,000 units deployed and operational

Disruptive business model

Executed contracts for 5,150 units pending regulatory approvals

Medical Screening as a Service (MSaaS) opens a recurring revenue model that has the potential to provide substantial revenues

ILLUSTRATIVE MODEL

POTENTIAL ANNUSL RECURRING REVENUE ASSUMING THE 5,150 CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL



Planning global mass deployment of 15,000 systems with a Pay-per-Scan subscription model

See slide 27 for full detail and assumptions



Strategic Shareholders

FUJI FOXCONN SK telecom

Exceptionally seasoned execution team

Healthcare and technology veterans from companies like GE, Philips, and highly successful, game-changing technology entrepreneurs

NANOX

Preventive screening

Early detection is key to preventive healthcare.

Treatable conditions, such as cancer, cardiovascular failures and others are often diagnosed too late.



NANOX

Early detection remains theoretical

2/3 of the world's population have no meaningful access to medical imaging

The majority of the remaining 1/3 suffer from weeks and months of wait time for access to medical scanners and diagnostic results.

NANOX

Why?

Medical imaging systems are too expensive and complex for mass deployment.

The key inhibitor

X-Ray source technology has not changed since its discovery over 120 years ago



Wilhelm Conrad Röntgen

The hot cathode



Current day X-Ray tube
Analog X-Ray source

Heats up a metal filament to 2,000° Celsius to produce the electron streams necessary for X-Ray emission

Main contributor to high-cost of imaging systems

The legacy analog X-Ray source

Requires extremely high-voltage, complex mechanics and special cooling to produce the electrons needed for X-Ray emission, resulting in an average $150,000 cost for the source alone

NANOX

The Nanox paradigm

A fundamental technological change in the X-Ray source

Will result in lower cost and smaller imaging systems

Which we expect will enable significantly higher availability of imaging services

Driving higher rates of medical prevention through early-detection.

NANOX

Introducing the novel Nanox X-Ray source

Novel silicon-based, low voltage, nano-scale cold cathode

Generating the electrons streams needed for X-Ray via cold field-emission technology



X-Ray Reimagined

Nanox MEMs X-Ray technology

- Technology originally developed by Sony and its partners to achieve a higher quality image for screens and monitors
- Sony invested substantial resources in the development of this technology for over a decade
- After acquiring the technology, our Japanese-Israeli team invested **over 8 years** developing a source for the medical imaging industry based on this technology
- Nanox-owned manufacturing facilities in Japan
- Signed agreement with SK Telecom for collaboration on a new Korean factory to increase Nanox MEMs production capacity
- Mature and optimized proprietary technology and production process with an exceptionally high-yield
- Strong IP portfolio with patents granted in USA, Israel, Japan and pending globally



NANOX CLEAN ROOM (JAPAN)

NANOX WAFER



Tech transformation

From



One metal filament heated to 2,000° Celsius requiring special cooling and rotation mechanics

To



100 Million nano-cones field on a silicon chip emitting digitally controlled electron streams under low voltage



NANOX

The Nanox tube

Commercially available
Digital X-Ray source

The Nanox Silicon
MEMs cold cathode

NANOX

The Nanox tube

Significantly smaller
Substantially more cost effective

LEGACY TUBE

$150,000 average cost

NANOX

~$100 estimated cost in mass-production

NANOX

Clinical quality imaging

Nanox I kVp: 50 I mAs: 0.4 I

Commercial device I kVp: 60 I mAs: 3.5

kVp - Kilovolt Peak. kVp is the component that controls the X-Ray penetration strength and subsequently QUALITY of the X-Ray beam produced. It is also what controls the CONTRAST or GRAY SCALE in the produced X-Ray film. The Higher the kVP the LOWER the CONTRAST.

mAs - MilliAmps per Second. This parameter controls the QUANTITY or the AMOUNT of X-Ray photons produced. This is also what dictates the radiation dose. The higher the mAs the higher the radiation exposure.

Clinical quality imaging

3D Image Reconstruction



NANOX X-Ray TUBE 40Kv, 2.5mA

The Nanox.ARC 3D computerized tomosynthesis

- New breed of medical imaging using revolutionary X-ray source
- Results in lower cost, less complex, and smaller imaging system
- Aims to democratize global availability



Multi-source imaging



- Enables simple architecture
- Stationary sources
- Minimal moving parts
- Energy efficient duty-cycle
- Rapid digital switching
- More clinical data

The benefits

Multi-modalities

Single source 2D X-ray



3-Source 3D Fluoroscopy



11-Source Axial Imaging

NANOX

RSNA 2020

- Live streaming presentation was performed with global audience of thousands
- Nanox single source live imaging
- Nanox.ARC multi-source live imaging

RSNA 2020

Nanox single source live imaging and radiologists diagnostics

On the left - the hand of Ran Poliakine, Nanox's CEO, as was taken during the 2020 RSNA live demo, using the Nanox single source device with the Nanox tube;

On the right - the hand of Anna Bertha Ludwig, Röntgen's wife. Röntgen himself took this iconic image in 1895

Nanox multi-source 3D tomosynthesis



On the left - single slice from a reconstructed 3D tomosynthesis image that was taken during the 2020 RSNA live demo using the Nanox.ARC, a multi-source device containing Nanox X-Ray tubes

On the right - a single 2D plain (conventional) chest image was taken in a leading hospital in Israel one day before the RSNA live demo. The same phantom (w/lesions) was used for both images

NANOX

Post-RSNA Press



Our plan

Disrupt the imaging market with a global service infrastructure for medical imaging

- Increase significantly medical imaging availability
- Deploy 15,000 units globally by YE2024 subject to Company financing & regulatory clearance
- Invest CAPEX and own the systems
- Operate a Pay-per-Scan, MSaaS business model
- Generate substantial recurring revenue stream once fully deployed

NANOX

Timeline and key milestones

1991

Sony and partners invest in Field Emission Display (FED) technology

2008

Sony achieves first FED TV prototype

2012 - 2019

8 Years

MBO by Japanese R&D team and establishment of Nanox; focus on medical imaging

First MEMS silicon tape-out and development of the Nanox X-Ray Source
Development of the Nanox.ARC

June 2019

Strategic collaboration with FUJI

Strategic collaboration with SK Telecom

FUJI

SK telecom

2020

Q3 2020

Secures $79M investment from strategic investors, including Foxconn, Industrial Alliance, SK Telecom
Submits 510(k) application of the Nanox.ARC 1

FOXCONN

Manufacturing agreement with Foxconn ensures manufacturing quality and consistency

H1 2020

Signs 8 pre-sale agreements for deployment of thousands of units with guaranteed substantial minimum annual service fees for at least 3 years from full deployment

H2 2020

Completion of IPO on NASDAQ raising $170 MM of net proceeds

Anticipate signing of additional pre-sale deals globally with minimum annual service fees

Nanox presents its technology in a live demo at the RSNA

2021-2024

from H1 2021

Ramp-up of manufacturing and systems deployments

Expected recurring revenue stream

H1 2021

Anticipated FDA approval of 510(k) submission for multi-source version by mid-year 2021

H2 2021
First commercial units expected to be manufactured and shipped to service providers

2024

Approx. 15,000 units expected to be deployed and operational globally

Addressable market

Expansion of the $21 Billion global medical imaging market through shift from CAPEX to MSaaS model

The X-Ray-based imaging market 2021-2024

Nanox addresses the market segments legacy vendors do not traditionally sell to



We do not compete over market share, we expand the total market

- We sell medical imaging availability
- We expect to provide systems to market segments existing X-Ray vendors don't target
- We target Urgent Care units (over 9,600 in the US alone), outpatient clinics, rural areas, countries with limited medical imaging availability (e.g., India, China, Africa)
- We believe the CAPEX market of hospitals, medical centers and clinics will migrate to an OPEX service-based model over time
- Nanox is pioneering this model today
- For certain medical imaging market participants, we plan to tailor our X-Ray source technology to their specific imaging systems and we expect to charge a one-time licensing fee upfront and receive recurring royalty payments for each system sold

NANOX

Flexible business model to drive adoption

MSaaS

ILLUSTRATIVE MODEL

POTENTIAL ANNUAL RECURRING REVENUE ASSUMING THE 5,150 CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL



At 20 scans per day, and $14 per scan revenue to NANOX and 23 days per month, the MSaaS model potentially generates over $397 Million in recurring revenues annually

Scans per day - LEGEND

- 7 - Minimum scans per day per system
- 20 - Nanox operational objective
- 60 - Estimated current global average

Pricing model & minimum annual service fee

- Pay-per-scan service business model
- Nanox covers CAPEX investment in systems and deployment
- **$40 total cost per scan as a global average based on current contracts**
- **Nanox revenue: $14 (out of the $40) per scan based on current contracts**
- Contracting regional service providers for marketing and operation of the service
- Current contracts provide a minimum annual service fee for 7 scans per day per system against regional exclusivity

- Total number of systems deployed may vary as per financing and final unit cost
- Price-per-scan will vary based on regional economics
- Minimum annual service fees will be backed by a standby letter of credit or financial guarantee upon receipt of local regulatory approval

NANOX

Contracted deployments

Current contracts for deals - 5,150 units (Pending local regulatory approval)

- Australia, NZ, Norway - 1,000 units
- Taiwan, Singapore - 500 units
- Italy - 500 units
- Spain - 420 units
- Mexico and Guatemala - 630 units
- Brazil - 1,000 units
- Russia - 500 units
- Belarus - 100 units
- South Africa - 500 units



Strategic Collaboration Agreements - 5,500 units

- USA - 3,000 units
- Korea, Vietnam - 2,500 units
- Units of contracted pre-sale deals, with experienced service providers, are expected to be delivered from H2 2021
- Deliveries are conditioned upon acceptance test approval and local regulatory clearance in each region
- Active pipeline of additional countries aiming to join initial wave of deployment

Minimum annual service fees

Nanox current contracts require a minimum annual service fee backed by a standby letter of credit or financial guarantee upon receipt of local regulatory approval and satisfaction of all conditions precedent under each agreement

Selected customer profiles

SPI Medical, S.A. de C.V. (Mexico)

- SPI Medical, S. A. de C.V. is a distributor of specialty pharma products and medical devices, operating with global leaders such as Abbott, Merck, Bayer and Eli Lilly, and medical imaging systems from Phillips, GE, Siemens, Planmed and Toshiba.
- Distributes to both the public and private sectors in Mexico and Guatemala.
- **Entered into an initial 7-year MSaaS agreement to distribute 630 Nanox Systems across Mexico and Guatemala[1]**
- **Anticipated $17 million[2] of minimum annual service fees to Nanox**



[1] Subject to regulatory approval and customer acceptance test
[2] Assumes 7 scans/day x 23 days/month x at $14 per scan x 630 units deployed

NANOX

Selected customer profiles

Promedica Bioelectronics s.r.l. (Italy)

- Promedica Bioelectronics s.r.l. has over 25 years of experience representing diagnostic imaging vendors such as Fujifilm, Siemens Medical Systems and GE Healthcare
- Also manages commercial strategic activities for multinational companies for the marketing of systems with MR-guided Focused Ultrasound (InSightec) and robotic systems for interventional radiology procedures (iSYS)
- **Entered into an initial 4-year MSaaS agreement to distribute 500 Nanox Systems across Italy[1]**
- **Anticipated $13.5 million[2] minimum annual service fees to Nanox**

PROMEDICA BIOELECTRONICS

[1] Subject to regulatory approval and customer acceptance test
[2] Assumes 7 scans/day x 23 days/month x at $14 per scan x 500 units deployed

NANOX

USA

Strategic collaboration with USARAD

- Over 250+ U.S. certified radiologists organization
- Providing online, remote radiology services across the U.S.
- 25% owned by Siemens Healthineers

USARAD.com RADIOLOGY-ON-DEMAND®

SIEMENS Healthineers



- Working with one strategic partner for nationwide deployments instead of operating a large direct sales force
- Aiming to place 3,000 systems nationwide in the next 2 years
- Urgent care centers, primary care physicians, outpatient imaging centers, chiropractors, veterinarians and more

Once cleared by the FDA we expect the Nanox.ARC imaging procedures will be covered by radiology CPT reimbursement codes

The Nanox infrastructure management platform

Increasing availability of medical imaging systems solves only half of the problem

Purpose built proprietary radiology software platform streamlines operations and analytics

- Radiology diagnostics remain a significant bottleneck
- All Nanox.ARC systems will be connected to the Nanox.CLOUD
- A proprietary software platform designed to streamline the radiology diagnostics services and provide billing control

Nanox.ARC



Nanox.CLOUD

3D Image Reconstruction

The Nanox.CLOUD

A central backbone of our imaging infrastructure that will provide the ability to scale with connectivity to robust services

- Built ground-up with automation, privacy and security in mind
- Expected to be HIPPA and GDPR compliant
- Enables integration into medical systems via APIs
- Full administrative and billing services



Regulatory clearance

FDA

- We expect to take a multi-step approach to the regulatory clearance process:
  - Submitted a 510(K) application in January 2020 relating to a single source digital X-ray version of the Nanox.ARC
  - Received an additional information request in March 2020, which we responded to in September 2020
  - Plan to submit an additional 510(k) application with respect to the multi-source Nanox.ARC and Nanox.CLOUD, which, if cleared, will be our commercial imaging system
  - We do not believe the Nanox X-ray source (the core component of the Nanox.ARC) will require a separate regulatory approval or clearance because the source is a Class 1 device, which is exempt from the 510(k) application process
- If cleared, we plan to deploy the first Nanox.ARC in the second half of 2021

CE and ROW

- CE submission expected in H1 2021. Clearance expected in H2
- Majority of ROW countries accept FDA or CE as a reference for local clearance
- Other countries will require separate submissions

NANOX

Global partnerships

Nanox's cloud-based service will enable medical imaging services globally through its partnerships

Strategic Partners

- SK telecom — 5G, MEMs manufacturing and APAC distribution
- FUJI — Mammography OEM
- FOXCONN — Manufacturing

AI & Image Transfer

- IMEDIS — Cancer detection
- Brainomix® — Stroke
- qure.ai — Chest & Head
- CureMetrix CAD That Works — Mammography
- AMBRA — Secure image transfer

Deployments

- USARAD.com RADIOLOGY-ON-DEMAND® — United States
- Golden Vine — Taiwan, Singapore
- PROMEDICA BIOELECTRONICS — Italy
- CLARITY medical solution / ROEL Group — Russia, Belarus
- apr / the Gateway group / SK telecom — Australia, Spain, New Zealand, Norway, Korea Vietnam
- AM — Brazil, S. Africa
- Mexica, Guatemala



The team

A strong execution team with decades of relevant experience and proven track record of large-scale global projects, medical business expertise and bringing innovation to market

Ran Poliakine

Chief Executive Officer and Chairman of the Board

The founder of the wireless charging industry, a entrepreneur focusing on global life-changing technologies and inventions across multiple verticals

Anat Kaphan

VP Product Marketing

Past VP Product and Marketing at Mazor Robotics, and a senior executive at Philips Medical and Lumenis, Ms. Kaphan holds an M.B.A. in international marketing from Tel Aviv University.

Itzhak Maayan

Chief Financial Officer

Mr. Maayan has served in financial leadership positions in multi-national companies including Perrigo, Cisco Systems, and Elscint.

Yoel Raab

Chief Technology Officer

A former medical executive at Intel and Orbotech, Mr. Raab has decades of product development experience, and a BSc. and MSc. in applied physics & microelectronics.

Adv. Tal Shank

VP Corporate Development

Mr. Shank has a background of development and counsel to a number of companies, starting as partner at Guy, Bachar & Co. Law Firm. Mr. Shank holds an M.B.A. and LL.M. from Tel Aviv University.

Gilad Yron

Chief Business Officer

Coming from Kornit Digital where he was Executive VP Global Business, and Stratasys, where he held the position of Senior VP Products, Mr. Yron is a veteran of international corporations.

Lydia Edwards

President, Nanox US

Ms. Edwards has spent 3 plus decades in management and leadership roles for medical and technology companies, including Packard Bell, The Ensign Group, and Nationwide Medical.

Hitoshi Masuya

Co-Founder, Japan Laboratories Manager

Mr. Masuya is a senior executive and investor who established and led a number of venture capital firms, corporates and startups worldwide.

Amir Ben Shalom, Ph.D.

Chief Science Officer

With over 250 patents granted and pending, Dr. Ben Shalom is a scientist, engineer, author, and a renowned expert in high-power analog circuits and electro-optics.

Shirly Kaufman Kirshenbaum

VP Human Resources

Former Human Resources Director of Israeli-American Council and Regional Human Resources Director and HRBP EMEA and Canada at ZIM Shipping Services Ltd.

Oren Vrubel

VP Research and Development

Former head of the R&D Division in the Israel Prime Minister's office and a graduate of the Technion Program of Excellence, Mr. Vrubel is experienced in solving unique challenges.

Elad Toister

VP Engineering

Mr. Toister has worked in R&D and engineering positions at various capital equipment companies; and holds an MBA and a B.Sc. in mechanical engineering from the Technion.

Omer Aviad

VP Software Development

15 years of experience in building system architecture and software design, and in leading software development projects for international technology companies

Guy Yoskovitz, Ph.D.

VP Clinical Innovation

A genomic expert with extensive knowledge in digital health, Dr. Yoskovitz holds a Ph.D. in Human Genetics, an M.Sc. in Medical Sciences and a B.Sc. in Computational Biology.

Bruce Edwards

VP Business Development

Mr. Edwards is an accomplished executive with extensive experience in growing successful businesses, and has founded several companies including Sunset Sleep Labs and Cambrix Publishing.

Ukyo Jeong

Director of Manufacturing

Mr. Jeong has decades of experience in semiconductor architecture, device physics and manufacturing operations, including front and back-end silicon device fabrication.

Joon Ho Jang

Head of Nanox Korea

Mr. Jang has been in the semiconductor industry for over 25 years, and has a long record of accomplishment in engineering work, global business development, and senior management.

Myung Keol Lee

General Manager AP Business Development

Mr. Lee is a veteran of the semiconductor industry with experience in international business development and in establishing of business networks in the Asia Pacific market.

NANOX

Advisory board

Morry Blumenfeld
GE Healthcare

Prof. Geoffrey D. Rubin
Duke University

Prof. Norbert Pelc
Stanford University

Ruth Atherton, Ph.D., J,D.
Bill & Melinda Gates foundation

Dr. Rafael Grossman
TED

Michael Jackman
GE Healthcare

Dr. Michael Yuz
USARAD.com Radiology-on-Demand

Prof. Peter Dawson
NHS University College London Hospitals NHS Foundation Trust

Prof. Yong-woo
SAMSUNG KANGBUK SAMSUNG HOSPITAL

Thomas Deckle
IBM

Professional and involved advisory board of physicians, radiologists, business veterans and global opinion leaders. The Nanox advisory board is an integral part of our think-tank for product roadmap and strategy.

NANOX

Progress since August IPO



NANOX

Summary

- Nanox is developing a digital source x-ray technology enabling a new generation of imaging devices that could significantly reduce the costs of medical imaging systems
- Allows for multi-source scanning due to the low cost of the x-ray source – which opens the door for innovative imaging systems and improved clinical value for diagnostics
- Aiming to significantly increase medical imaging availability and affordability worldwide
- We believe the industry should shift to a service based, pay-per-scan (MSaaS) business model vs. the legacy capital investment model
- We believe that the industry should migrate to an open platform "App Store" model with multiple diagnostics support applications to choose from instead of a one "walled-off" software package
- We believe medical imaging should migrate to a universally-connected, global cloud service with superior accessibility to medical data and its analysis (in conformance with all applicable privacy laws) for the benefit of preventive healthcare and global health analytics and studies
- We plan to proactively promote our business plan via deployment of 15,000 units globally by year end 2024 and through partnerships





NANOX

Thank You

Enabling a system-level quantum leap

From

Analog
Single-source
Single-modality
Large and complex
Costs Millions of dollars

To



Digital
Multi-source
Multi-modalities
Small footprint
Costs tens of thousands of dollars

Multi-modalities



- Single source 2D X-ray
- 3-Source 3D Fluoroscopy
- 11-Source Axial Imaging